Although altered expression of some enzymes of the TXN system was already observed in selected hematologic malignancies (Agrawal‐Singh et al., 2012; Sewastianik et al., 2016; Trzeciecka et al., 2015), our knowledge on the influence of these enzymes on cancer progression and response to therapy of BCP‐ALL is currently limited. This evidence concerns the gene TXN and acute lymphoblastic leukemia.